Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation

Matt Stevenson,1* Abdullah Pandor,1 Marrissa Martyn-St James,1 Rachid Rafia,1 Lesley Uttley,1 John Stevens,1 Jean Sanderson,1 Ruth Wong,1 Gavin D Perkins,2,3 Ronan McMullan4,5 and Paul Dark6,7

1School of Health and Related Research, University of Sheffield, Sheffield, UK
2Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
3Heart of England NHS Foundation Trust, Coventry, UK
4Centre for Experimental Medicine, Queen’s University Belfast, Belfast, UK
5Belfast Health and Social Care Trust, The Royal Hospitals, Belfast, UK
6Institute of Inflammation and Repair, University of Manchester, Manchester, UK
7Salford Royal NHS Foundation Trust, Salford, UK

*Corresponding author

Declared competing interests of authors: Gavin D Perkins is a member of the Health Services and Delivery Research (researcher-led) panel. Ronan McMullan reports grant funding (2012–17) as a member of the Innovate UK-funded consortium, with industry partner (Randox Ltd), to develop and validate a novel point-of-care diagnostic test for sepsis. Paul Dark reports grants from Innovate UK (Technology Strategy Board) during the conduct of the study.

Published June 2016
DOI: 10.3310/hta20460

Plain English summary

Three sepsis tests for identifying bloodstream bacteria and fungi

Health Technology Assessment 2016; Vol. 20: No. 46
DOI: 10.3310/hta20460

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Sepsis is estimated to cause 37,000 deaths per year in the UK. Early and appropriate treatment can reduce the risk of sepsis-related death. New tests can detect bacteria and fungi in the blood much quicker than standard practice, allowing treatment changes to occur faster.

This report looked at the clinical effectiveness and cost-effectiveness of three tests: LightCycler SeptiFast Test MGRADE® (Roche Diagnostics, Risch-Rotkreuz Switzerland); SepsiTese™ (Molzym Molecular Diagnostics, Bremen, Germany); and the IRIDICA BAC BSI assay (Abbott Diagnostics, Lake Forest, IL, USA). These tests are designed to provide the clinician with a result regarding whether or not a patient has sepsis and which bacterium or fungus is the cause, and are much quicker than current methods. A review of the published literature showed that the tests are better at correctly identifying patients without sepsis than those with sepsis, but that all three tests are imperfect.

However, because of limitations in reporting and study quality, these data should be treated with caution. A review of the published literature showed that the tests can decrease the time at which the clinician received the result and decrease the time at which some patients changed to a better treatment within clinical trials. However, these benefits may not be realised in clinical practice. Furthermore, key benefits (reduced mortality, reduced length of stay in intensive care units and hospital, and reduced costs of treatment) of the new tests had yet to be proven within clinical trials. Expert clinicians were asked to provide estimates of these benefits and the answers were, on average, positive, although individual clinicians held widely different views.

Given the markedly different results produced when the published evidence of benefits were used and when the estimates from the clinicians were used, no firm conclusions could be made regarding the likely cost or benefits associated with the three tests. In order to provide better estimates, studies should be undertaken where information from the tests is allowed to change clinical practice and for these results to be compared with those from current practice.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 14/69/04. The protocol was agreed in May 2015. The assessment report began editorial review in August 2015 and was accepted for publication in November 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGIAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk